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This paper is the first in a new Clinical Feature Series that will be a regular fea-
ture in future issues of The Yale Journal ofBiology andMedicine. Papers in the
series will focus on cases and disease processes ofgeneral interest to the prac-
ticing clinician, with the goal being to present the perspectives ofexpert clini-
cians regarding the accurate diagnosis and effective treatment of the diseases
being discussed. The following case was presented at Medical Grand Rounds at
the Yale-New Haven Hospital and the Yale School of Medicine by John P.
Hayslett, Professor of Medicine (Nephrology) with accompanying analysis of
pathological specimens by Dr. Hugh Carey, a Postdoctoral Fellow of the
Pathology staff. The patient whose caseis presented was also present todescribe
her experience with the illness and the course oftreatment.
INTRODUCTION
Dr: John P. Hayslett:
The clinical features of lupus nephropathy will be illustrated by a patient who has
been under my care for the past eight years. This patient has graciously accepted an invi-
tation to participate in this conference to comment on experiences with her illness and
treatment. Dr. Hugh Carey, Department of Pathology, will discuss the histopathological
findings observed in the series of renal biopsies performed to determine the course of
treatment.
CASE PRESENTATION
The clinical course began in 1981, as shown in Figure 1, when she developed a facial
rash, buccal ulcerations, arthralgias and arthritis and low-grade fever, and the diagnosis of
systemic lupus erythematosus was made. She was treated with prednisone and plaquenil
and achieved some symptomatic relief, although at a dose ofprednisone above 15 mg/day
she experienced substantial side effects in the form of impairment of recent memory, a
reduction in attention span and increased fatigability.
Proteinuria was first observed in March 1987, when renal function was normal.
Subsequently she experienced aclinical flare with hairloss, facial rash, recurrence ofbuc-
cal ulcerations and low-grade fever. In the fall of 1987, a renal biopsy was performed at
another institution. On the basis ofthe renal biopsy, the dose ofprednisone was increased
to about 30 mg/day, which caused considerable side effects.
aTo whom all correspondence should be addressed: John P. Hayslett, M.D. Section ofNephrology,
Department ofInternal Medicine,YaleUniversity School ofMedicine. 333 CedarStreet New Haven,
CT 06510.
CAbbreviations: AZCY, oral azathioprine and cyclophosphamide; IVCY, intravenous cyclophos-
phamide; POCY, oral cyclophosphamide; AZA, oral azathioprine.
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Figure 1. Clinical course ofpatient from onset ofsystemiclupus erythematosus in 1981 to 1995.
I initially met the patient and her husband in January of 1988 when they sought my
opinion about the prospect of pregnancy. On physical examination she had an erythema-
tous rash on her face and over her sternum and petechiae on her hard palate. There was a
livido-reticular reaction on the fingers and hands, consistent with peripheral vasospasm.
She also had dependent pitting edema and appeared to be chronically ill. Because an
assessment ofthe activity ofsystemic lupus erythematosus was an important factor in her
candidacy for pregnancy, we retrieved the renal biopsy that was performed at that other
institution for review. Dr. Carey, will you please show the first renal biopsy?
Dr. Hugh Carey:
The histopathology of lupus nephritis is predominantly the study of glomerular
immune complex disease, and I will limit the focus of discussion to that, although tubu-
lo-interstitial and vascular lesions frequently play a significant role.
I will briefly review normal glomerular histology. The glomerulus shown in Figure 2
is enclosed within Bowman's capsule and consists of a delicate bundle ofcapillary loops
supported by a dynamic cellular structure, the mesangium. Endogenous glomerular cells
include the mesangial cell, endothelial cell, visceral epithelial cell or podocyte and the
parietal epithelial cell.
By electron microscopy (Figure 3), one can see a discrete section of a normal
glomerulus with mesangium, associated capillary loops and Bowman's space. The
mesangium contains themesangial cell and associated modestly electron-dense mesangial
matrix material. The capillary loops consist of an inner, modified, fenestrated endotheli-
um, a trilaminar basement membrane and the outer interdigitating foot processes arising
from the podocytes. Immune complexes may form either within the mesangium, within
the subepithelial space between foot processes and the basement membrane or within the
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Figure 2. Photonicrograph of normal glomerular morphology by light microscopy.
Figure 3. Electron micrograph of a normal glomerular capillary loop.
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subendothelial space between basement membrane and endothelium. Characteristics of
antigens, antibodies and immune complexes are some ofthe factors that determine where
immune complexes are localized, either by deposition of circulating immune complexes
or, more commonly, by in situ formation. Recently, it has been demonstrated that lupus
autoantibodies can bind directly with cross-reacting native glomerular antigens, and thus,
perhaps be involved in site-specific immune complex deposition.
The classification of lupus nephritis has evolved over decades, and its function is to
separate histological variations that carry different prognoses and warrant different thera-
pies. Lesions are dynamic and may transform from class to class either spontaneously or
in response to therapy. Classification often overlaps within a given biopsy, but typically,
final stratification is based on the worst prognostic features. The current World Health
Organization classification of lupus nephritis (Figure 4) is: Class I, normal; Class II,
mesangial proliferative glomerulonephritis; Class III, focal proliferative glomerulonephri-
tis (involving less than 50 percent of glomeruli); Class IV, diffuse proliferative glomeru-
lonephritis (involving greater than 50 percent of glomeruli); and Class V, membranous
nephropathy. This diagram (Figure 5) highlights the histological variations of lupus
nephritis with emphasis on the ultrastructural localization ofimmune complexes. Though
certainly a dynamic complex interplay between antibody-driven, cell-mediated, and vas-
cular-specific abnormalities ultimately determine the specific pathology for a given
patient, there is substantial evidence demonstrating that the site of glomerular immune
complex deposition is a crucial determinant of both histological severity and, ultimately,
clinical presentation. These immune complex features will be utilized to illustrate the
characteristic pathological and clinical features ofthe different classes oflupus nephritis.
Class II Lupus or mesangial proliferative glomerulonephritis is characterized by an
increase in glomerular mesangial cellularity and matrix, and invariably there are mesan-
gial immune complexes by electron microscopy. Class II lesions are typically associated
with mild to moderate proteinuria and normal to minimally decreased glomerular filtra-
tion rate. Sequestration within the mesangium partially shields immune complexes from
more direct interactions with circulating inflammatory mediators. Factors that likely favor
mesangial localization include intermediate size immune complexes with high affinity and
avidity.
Class III and IV lupus nephritis, the focal and diffuse proliferative variants, respec-
tively, are characterized by glomerular cellular proliferation and inflammatory changes
Figure 4. World Health Organization classification oflupus nephropathy.
LUPUS NEPHRITIS: WHO CLASSIFICATION
1. NORMAL
11. MESANGIAL PROLIFERATIVE GN
I1. FOCAL PROLIFERATIVE GN
IV. DIFFUSE PROLIFERATIVE GN
V. MEMBRANOUS NEPHROPATHY
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Figure 5. Demonstration of the WHO classification oflupus nephropathy by the distribution
ofelectron-dense deposits.
that may or may not include necrosis, thrombosis, or crescent formation. Subendothelial
deposits are invariably present, and it is the proximity of these deposits to the vascular
interface that facilitate an inflammatory reaction by maximizing exposure to circulating
inflammatory mediators. Typically, patients with Class III or IV lupus nephritis present
with nephritic urine sediment and frequently have mild ormoderately depressed glomeru-
lar filtration rate, though clinically "silent" Class III and IV lupus nephritis is well
described. Subendothelial deposits form either directly at the endothelial interface, or
migrate from themesangium secondary to high rates ofmesangial immunecomplex depo-
sition, impaired mesangial clearance, or both. Factors that favor subendothelial localiza-
tion include a vigorous antibody response and relatively larger immune complexes with
high affinity and avidity. Cationic antigens or antibodies may selectively bind to the
subendothelial region of the basement membrane because ofnative negative charges.
Class V or membranous nephropathy is characterized by mesangial expansion and
diffuse subepithelial immune complex deposition. Mesangial immune deposits are fre-
quently present, and this feature has significant predictive value in separating lupus asso-
ciated from idiopathic membranous nephropathy. Similar to the mesangium, the subep-
ithelial space is well protected from direct contact with many circulating inflammatory
mediators. Patients usually present with moderate to nephrotic range proteinuria and well-
preserved glomerular filtration rate. Factors that favor subepithelial immune complex
deposition include small, soluble immune complexes with low avidity and affinity that
81Hayslett and Carey: Lupus nephropathy
likely form by in situ deposition. Again, cationic antigens may demonstrate a strong affin-
ity for anionic charges in the subepithelial region.
A representative glomerulus from the first renal biopsy (Figures 6a and 6b) shows
marked hypercellularity, mesangial expansion and segmental necrosis with nucleardebris,
or karyorrhexis. Large subendothelial immune complexes are present. Rare subepithelial
deposits are seen. Thus, this patient has WHO Class IV diffuse proliferative glomeru-
lonephritis with necrosis.
Dr. Hayslett:
At this time, the patient had active disease on physical examination and by history, as
well as proteinuria (2.5 gm/day) and hypoalbuminemia; dependent edema was secondary
to nephrotic syndrome. The renal biopsy performed two months earlier showed aClass IV
lesion that reflected active lupus nephritis. I suggested that pregnancy should not be
attempted at that time because observational studies indicated that the likelihood ofa suc-
cessful pregnancy is much greater if undertaken at a time when disease is inactive. I also
indicated that the initial interpretation of the renal biopsy underestimated the severity of
her renal disease and suggested that she would benefit from immunosuppressive therapy
to suppress the injury reaction.
Our approach to the treatment of acute lupus nephritis, based on studies that will be
discussed subsequently, involved the administration of an immunosuppressive drug, and a
glucocorticoid in an amount sufficient to suppress extrarenal manifestations of systemic
lupus erythematosus, for at least two years. In addition, we advocated re-examination of
renal histopathology by biopsy after two years to determine the effectoftherapy on thepat-
tern on renal injury because measures ofrenal function and serological tests are notprecise
markers ofthe response to treatment. The patient was therefore treated with azathioprine,
Figure 6a. The renal lesion by light microscopy in the first renal biopsy in 1987.
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Figure 6b. Electron microscopy of first renal biopsy demonstrating a large subendothelial
deposit and smaller subepithelial and intramembranous deposits.
1 mg/kg body weight, and prednisone was continued in a dose of about 15 mg/day.
Azathioprine was advantageous in this patient because itdoes notinduce infertility, as alka-
lating drugs such as cyclophosphamide are likely to do.
During the first 12 months of treatment, the extrarenal manifestations of disease
resolved, and, as shown by Figure 1, protein excretion was reduced from nephrotic levels
to 500 mg/day. Apparently because of clinical improvement, her primary physician dis-
continued azathioprine. Five months later, as shown in Figure 1, she experienced a severe
flare and a recurrence ofnephrotic syndrome.
Although the initial course suggested that azathioprine had substantially suppressed
the acute inflammatory reaction in the kidney, this potential response to treatment was not
documented by renal biopsy. It was notpossible, therefore, todistinguish between a recur-
rence of a severe inflammatory reaction and a transformation from the lesion seen on the
83Hayslett and Carey: Lupus nephropathy
first biopsy to a membranous lesion (Class V). Because a distinction between these two
possibilities would influence our therapeutic decision, I recommended repeating the renal
biopsy.
D)r Carey:
By light microscopy, there was significant mesangial widening, markedly thickened
capillary loops and diffuse cellular proliferation. Leukocytes were seen within capillary
loops. There was focal necrosis. By electron microscopy, there was mesangial expansion
with mesangialization ofthe basement membrane, and abundant subepithelial and suben-
dothelial deposits were present. This lesion, therefore, represented a Class IV diffuse pro-
liferative glomerulonephritis.
Dr Hayslett:
It seemed likely, as noted, that the patient had responded to azathioprine and that
relapse ofboth renal and non-renal aspects ofdisease occurred because of premature ter-
mination of the immunosuppressive agent. We therefore reinstituted azathioprine in the
same dose as before. Although the non-renal symptoms resolved after several months of
treatment, heavy proteinuria persisted. At this time, I was concerned that she was refrac-
tory to azathioprine and, if so, that progressive damage to renal parenchyma could lead to
renal insufficiency. I decided to examine the renal histopathology ten months after start-
ing the second course ofazathioprine. Dr. Carey, will you discuss the results of this biop-
sy?
Dr Carey:
At this time, there was significant proliferation in the majority ofglomeruli. There was
also small cellular crescent formation indicative ofnecrosis. Capillary loops were markedly
thickened. By electron microscopy, there were diffuse large subepithelial deposits, as seen
in membranous nephropathy; but focally, within the subendothelial space, there was persis-
tence ofsignificant subendothelial deposits. So again, we have a Class IV diffuse prolifera-
tive glomerulonephritis with some focal necrosis, although severity was reduced compared
to the previous biopsy. There was an increasing background of subepithelial deposits or
membranous transformation.
Dr. Hayslett:
The primary goal of treatment was suppression ofthe acute inflammatory reaction in
the glomerulus and resolution ofsubendothelial deposits ofimmune complexes. Since this
aim was not achieved after nearly a year of therapy with azathioprine, it seemed reason-
able to change the immunosuppressive agent. Then, as well as now, the only alternative
drug was cyclophosphamide. A recent report in 1986 from a National Institutes ofHealth
study suggested that intermittent intravenous therapy was at least as good as daily oral
treatment [1]. I therefore offered thepatient a choice ofeither mode ofadministration, and
she chose the intravenous regimen. Treatment was continued for two years in a dose of
500 mg/M2 at monthly intervals for the first twelve months, and thereafter, at intervals of
three months.
By the end ofthe first year oftreatment, urine protein excretion was reduced to about
500mg/day and reached lower levels in the second year. Extrarenal manifestations ofsys-
temic lupus erythematosus had completely resolved. We performed renal biopsies after
12 months to determine whether the injury pattern had improved and again at the end of
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therapy to establish a baseline evaluation before terminating cyclophosphamide. Dr.
Carey, will you show the results?
Dr: Carey:
This is a silver stain ofa typical glomerulus after one year ofcyclophosphamide ther-
apy (1991) (Figure 7). Capillary loops were diffusely thickened. Cellularity is moderate-
ly increased but there is no evidence ofan inflammatory infiltrate or necrosis. By electron
microscopy (Figure 8), punctuated along the subepithelial space are numerous large
subepithelial deposits; no subendothelial deposits were present. Transformation to a Class
V membranous lesion was complete. Another biopsy, a year later, again showed mesan-
gial widening by silver stain; cellularity was normal, the basement membrane was still rel-
atively thickened, and, by electron microscopy, there were large subepithelial electron-
dense deposits. The patient had a persistent Class V membranous lupus lesion.
Dr. Hayslett:
At this time, we had biopsy evidence that the acute inflammatory reaction had
resolved and that peripheral subendothelial deposits had disappeared. The proliferative
glomerulonephritis initially observed had transformed to a membranous nephropathy,
with only negligible amounts ofinterstitial scarring. Renal function was normal and pro-
tein excretion was near normal. We discontinued cyclophosphamide therapy, but contin-
ued prednisone at a low dose of 10 mg/day for a year and a half. She has received no ther-
apy for the past fifteen months, and measures ofrenal function have remained normal. We
continued to monitor laboratory parameters at three-month intervals for possible signs of
recurrence.
Figure 7. Renal lesion by light microscopy offourth renal biopsy in 1991, after 12 months of
cyclophosphamide treatment, showing a Class V pattern ofinjury.
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DISCUSSION
Dr Hayslett:
I will start this discussion with the question: can women with systemic lupus erythe-
matosus safely carry pregnancy to a successful outcome? Systemic lupus erythematosus
is a disease of young women during reproductive years with a peak appearance at age 18
to 19. The issue ofwhether it is safe to attempt pregnancy is avery important issue forthis
group of patients. It was previously thought that pregnancy and systemic lupus erythe-
matosus did not mix, because the outcome of pregnancy was an ominous one. Women
with this disease were, therefore, advised against pregnancy, and ifthey became pregnant,
were advised to terminate. During the last fifteen years, however, there have been several
studies which indicate that the outcome depends on the activity ofdisease at the time that
~~~~~~~~~~~YN _11! 1Va
Figure 8. Electron micrograph of the same renal biopsy shown by Figure 7, demonstrating a
typical membranous pattern with subepithelial deposits.
86Hayslett and Carey: Lupus nephropathy
pregnancy is initiated [2]. In women who are in complete clinical remission for six months
to a year at the time of conception, the incidence of flares is reported to be low and usu-
ally mild, and usually subside after delivery. In contrast, when pregnancy began with
active disease, the incidence of flares was much higher; these were usually more severe
and sometimes resulted in irreversible organ death. Pregnancy outcome correlated with
maternal disease activity: that is, when the maternal disease was quiescent there was a
high fetal survival, which averaged 90 to 100 percent in the four series where data were
available for this analysis. However, in pregnancies in which there was active maternal
disease, fetal survival was reduced to about 70 percent. A favorable outcome included
women who had initially had severe renal involvement, as in this woman's case, and even
renal insufficiency, if there was no clinical evidence of systemic lupus erythematosus
activity immediately prior to the onset ofpregnancy. In this case, the issue ofhaving chil-
dren was resolved because she and her husband successfully and happily adopted two
children.
When this patient sought advice about the possibility of a successful pregnancy out-
come, she exhibited active systemic disease and a diffuse proliferative glomerulonephri-
tis. My answer to her inquiry, as well for her own well-being, depended on our ability to
control her active disease and reverse her severe nephropathy that had resisted acceptable
levels of glucocorticoids. I will focus the remaining portion of the discussion on three
questions: 1) Does the risk for renal failure correlate with specific types of renal injury?
2) Can the pattern of renal injury be altered by drug therapy? and, if so, 3) What type of
drug treatment appears to be most efficacious? In the 1960s, it was clear that the outcome
of patients with lupus nephritis was predicted by the pattern of injury. Renal failure was
most often associated with a diffuse proliferative glomerular nephritis, in contrast to other
histopathological lesions. In the 1970s studies that analyzed renal biopsy material by elec-
tron microscopy showed that among patients with a proliferative lesion, the presence of
subendothelial electron-dense deposits was a singularly important harbinger for progres-
sive disease and renal failure [3].
A report from this institution in which intervention with an immunosuppressive agent
was employed strengthened the association between the presence of subendothelial
deposits in peripheral capillary loops and a poor renal outcome, and demonstrated that a
severe renal lesion could be modified. In this analysis, 31 patients with a Class IV lesion
were treated with azathioprine and low-dose prednisone [4]. A renal biopsy was per-
formed before starting treatment and two years later. At the end offollow-up, which aver-
aged 40 months, patients were classified as improved (normal serum creatinine and pro-
tein excretion), stable (the same but with low-grade proteinuria), or deteriorated (renal
insufficiency and/or nephrotic syndrome). At the end of follow-up, nearly all patients in
the improved/stable category who had a second biopsy exhibited either normal histology
or a membranous pattern on the second renal biopsy, with complete resolution of suben-
dothelial electron-dense deposits, as shown in Figure 9. In contrast, one-third ofthe group
were classified in the deteriorated category by clinical criteria, and all patients who had a
second biopsy had persistent subendothelial deposits. The results of this series, therefore,
showed that lupus nephropathy could be modified by treatment and highlighted the risk
posed by subendothelial deposits for progressive renal disease.
Observational studies performed at Yale on a larger number of patients with lupus
nephritis, by biopsy from 1967 to 1983, have subsequently been reported [5]. Eighty-
seven patients were analyzed. Nearly 80 percent had a Class III or IV lesion, and most
were treated with a combination of azathioprine and low-dose prednisone. Follow-up
averaged twelve years and renal and patient survivals are shown in Figure 10. Renal sur-
vival was 90 percent and patient survival was 77 percent. A poor renal outcome was pre-
dicted by renal insufficiency and heavy proteinuria at time of biopsy, and by the
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Figure 9. Demonstration that preserved renal function correlates with resolution of glomeru-
lar hyperceliularity and subendothelial deposits.
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histopathological findings of an active proliferative lesion, subendothelial deposits and
evidence oftubulointerstitial inflammation and scarring. Non-renal deaths were predicted
by co-morbid disease, mainly atherosclerotic disease and hypertension and older age.
Delay in initiating immunosuppressive therapy was associated with a higher incidence of
renal failure than when therapy began soon after the appearance of clinical renal disease
[6]. A second renal biopsy was performed in 42 of these patients [7]. As in the earlier
study, the second biopsy showed a decrease in active inflammation and an increase in
parenchymal scarring, a decrease in subendothelial deposits and an increase in membra-
nous transformation. This analysis was consistent with the notion that suppression of the
active renal lesion with clearing ofsubendothelial deposits was associated with preserved
renal function.
Similar results were reported from Europe by Dr. Ponticelli in a series of43 patients
with Class III or IV lupus nephropathy [8]. These patients were treated with pulse steroid
treatment monthly for three months and then with low-dose steroids. Thirty-one of these
patients also received oral immunosuppressive agents, either azathioprine or cyclophos-
phamide. At ten years follow-up, the renal survival was 83 percent and patient survival
was 75 percent. Death was primarily associated with atheroscleratic disease in older indi-
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Figure 11. Summary data ofNIH prospective trials of treatment oflupus nephritis [1].
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viduals. Together with our experience this study indicates that renal failure can be pre-
vented even in patients with the more severe forms oflupus nephropathy with therapy that
usually combines an immunosuppressive agent with prednisone.
Besides these observational studies, it is important to discuss the prospective study
performed by the Rheumatology Section at the National Institutes of Health [1]. This
study has had a profound effect worldwide on the treatment oflupus nephritis. A trial was
begun in 1969 and closed in 1976 to compare oral prednisone with the oral administration
ofazathioprine orcyclophosphamide. Patients wererandomized to one ofthe three groups
ifthey met entry criteria for the study. Four years later, a second trial was initiated, which
compared oral prednisone to two other experimental groups, one with both azathioprine
and cyclophosphamide administered orally and another with cyclophosphamide given
intravenously at three-month intervals, The second study was closed in 1981. The results
ofboth trials were reported in 1986 [1] and this Figure 11 summarizes the results by show-
ing the incidence ofrenal failure by cumulative survival analysis, with some patients fol-
lowed for as long as 160 months. Regarding the prednisone control group, Group 1
includes all patients treated since 1969, apparently including patients entered afterthe first
study was closed in 1976. Group IA indicates the control group for the second trial which
analyzed combined azathioprine and cyclophosphamide (AZCY)C and intravenous
cyclophosphamide (IVCY). Most patients had proliferative glomerulonephritis by light
microscopy; biopsy material was not analyzed by electron microscopy. The risk for renal
failure was similar for patients treated with oral azathioprine, oral cyclophosphamide and
prednisone (Group 1). Regarding the second trial there was no difference between the
experimental groups AZCY and IVC, and the concurrent Group IA. In a subsequent
study, published in 1991, when followup was extended to 220 months, the AZCY and
IVCY groups were said to differ significantly from control [9]. However, in that report,
the control appeared to include historical controls enrolled before the experimental groups
were initiated, as well as concurrent controls. On the basis ofthese data, the investigators
conclude that IVCY was superior to othermethods in the treatment oflupus nephropathy.
Although prospective by design, I believe it is questionable whether the study is supe-
rior to observational studies regarding the efficacy of different treatment regimens.
Hopefully, others in this room can be induced to look critically at the design and inter-
pretation of these experimental trials. To me it appears that the small number ofpatients
in each group, abouttwenty, substantially reduces statistical powerbecause ofrisk forran-
dom error, especially in a disease with a highly variable course. It should be noted that
patients were not initially randomized for apparent risk factors for poor outcome. In con-
trast to the usual procedure for scientific study, a clear plan for the duration oftherapeu-
tic regiments and/or end-point for final analysis has never been defined. Regarding analy-
sis, I am concerned aboutcomparing multiple experimental groups to a single control, the
use of non-concurrent controls in analysis, and employment of sequential analyses of the
same populations, presumably well beyond time ofadherence to specific treatment proto-
cols. For these reasons, therefore, I do not find this study compelling in selecting treat-
ment for patients with lupus nephropathy.
A review of medical reports and analysis of data, however, are only part of the dis-
cussion of an illness; another part is how the illness affects the life ofindividual patients.
I, therefore, welcome the comments ofthe patient whose course was described earlier.
Will you tell us about the symptoms you experienced when systemic lupus erythe-
matosus first began?
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Patient:
The first symptoms that I experienced were in the summer of 1981 when I had gone
to the beach and developed redness on my face. Since the redness did not go away or
change color, I became concerned. I went to a dermatologist who took a biopsy from my
face. When the results of the biopsy came back, he told me that I had lupus. He told me I
was lucky because he said it wasjust discoid lupus, and that I should start taking medica-
tion. Since I did not know what the disease was, I elected not to take any medication for
about four months. I then began to feel arthritic with pain in my arms, in myjoints and in
my pelvis. I also started getting severe cracks in my gums and sores in my mouth. I then
agreed to take whatever was indicated and was started on prednisone and plaquenil, and
within hours, my pain was gone and I was a new person. That began my treatment with
prednisone for 11 years. Everything seemed fine until 1987 when I again began to expe-
rience hair loss, fatigue and constant headaches. I went to another doctor, who thought I
should get a kidney biopsy, which I did at another hospital.
Dr. Hayslett:
One type of treatment that is very popular right now is cyclophosphamide by intra-
venous infusion, which you received for two years. Could you briefly indicate how you
felt from this?
Patient:
I felt pretty bad. Zofran (ondansetron) came out about halfway through my treat-
ments. Before that I took Cytoxan (cyclophosphamide) for about a year, every month. For
several days before each treatment it was very difficultpsychologically knowing thatI was
going to receive the treatment. When I got to the hospital, I would go into a room where
they would put in IV needles. They gave me one drug to counteract nausea and another
drug to calm me down. I guess that by the time I got the Cytoxan I was very drugged. I
was able to walk out of the hospital but I had to be taken home by my husband. I then
started drinking water because Dr. Hayslett said I should not have the medication in my
system very long and I needed to flush it out. I felt nauseous after the treatment, which
made it more difficult to drink, although I did anyway. I had to take more anti-nausea pills
because the nausea continued for about three days, after which things returned to normal.
Knowing that this was going to happen every month made it very difficult for me the first
year. After Zofran came out, the actual treatment was easier and I was able to walk out of
the hospital without feeling drugged or groggy.
Something that apatient with lupus, or any patient who has a disease that she is going
to live with for the rest of her life, needs to have is an understanding of what is happen-
ing in their body and as much control as possible over what is going on. A problem that
many patients face is the varied perspectives that different doctors have on what the
patient should know about the disease. Patients with lupus often are forced to change doc-
tors to find one who will treat them like intelligent people and explain the results of the
tests. Dr. Hayslett, for example, lets me see the results of all my lab tests. Many doctors
just refuse to let patients know anything, and that is not going to work. It is bad enough to
know you have something you are notgoing to be able to getrid of, but ifyou do not know
if you are getting better or worse, you become more frightened and that may even con-
tribute to the disease.
In 1988, I was trying to get pregnant. I had a doctor who was trying to help me get
offthe medications I was taking, which includedplaquenil andprednisone. Atfirst he took
me off one drug on the basis of some blood and urine tests, and then he took me off the
other. Then I went to a fertility specialist because I was healthy at the time, and I wanted
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to conceive as soon as possible. At that time when the fertility specialist asked my doctor
for a letter saying it was okay to get pregnant, he wrote back saying absolutely not, that
the morbidity and mortality oflupus patients is such that they should not get pregnant. As
a result, the fertility specialist would not see me anymore, and this is when I first went to
see Dr. Hayslett to see ifit was safe to become pregnant. He said he wanted to make sure
thatmy body was okay before going further. Since further studies showed thatmy kidneys
had actually gotten worse, he suggested that I should start on Imuran (azathioprine) ther-
apy and consider another alternative because getting pregnant, at least at that time, might
exacerbate the lupus. At that time, we had an opportunity to consider adopting forthe first
time, and we realized that it was something we would be able to do, in addition to having
our own biological child. In 1991, we adopted ourfirst child, and in 1994, we adopted our
second. They are much more beautiful than anything we could have made!
Dr Hayslett:
Before closing the discussion in this Grand Rounds, I would like to indicate that the
clinical course of systemic lupus erythematosus is not necessarily as hectic as experi-
enced by this patient or patients included in the reports that I have discussed. An inter-
esting paper was reported from southern Sweden a few years ago on all patients who
developed systemic lupus erythematosus between 1979 and 1986 in a defined popula-
tion of 163,000 [10]. All patients were diagnosed and managed by one clinic with three
physicians. The incidence ofnew cases was four per 100,000 adults per year. The cumu-
lative organ system involvement is shown in Table 1, which indicates that skin and mus-
culoskeletal manifestations were encountered by most patients, but that specific organ
Patients Patients
-igoe tiagnosed
Entire study 1979-1986 before 1979
Manifestation group (n=86) (n=50) (n=36)
Mucocutaneous 77 74 81
Marrash 43 34 56
Discoid lupus 23 24 22
Photosensitivity 52 50 54
Oal ulcers 13 12 14
Musuloskeletal 98 96 100
Arthritis 98 96 100
Myositis 3 2 6
Serositis 62 54 72
Glomerulonephritis 30 24 39
Neuropsychiatric 47 40 56
Epilepsy 5 6 3
Psychosis 8 8 8
Cerebralinfarction 8 6 11
Hematologic 49 42 58
Leukopenia 42 38 47
Thrombocytopenia 10 6 17
Hemolytic anemia 2 2 3
*Numbers are percentages
Table 1. Cumulative organ system involvement in all patients with systemic lupus erythe-
matosus living in a defined region ofSweden [10].
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involvement was much less common. Major clinical flares occurred in about 60 percent
during the first year of illness and fell to about 10 percent in subsequent years. In the
entire group of 89 patients, 18 received no specific treatment and eight received anti-
malarials only. Sixty-one patients were treated with glucocoricoids, usually in low dose,
and eighteen were treated with immunosuppressive agents, mostly oral azathioprine. Of
twenty-six patients with clinical evidence ofrenal disease, the glomerular filtration rate
was less than 50 ml/min in sixteen. Ofthese, only two developed renal failure. The cal-
culated patient survival of 95 percent and the incidence of disability was similar to the
rates in an age-matched Swedish population. This synopsis, I believe, gives a more
accurate picture of systemic lupus erythematosus as it generally occurs.
In summary, the outlook for patients with lupus nephritis is much better than report-
ed in the past. Patient survival is near normal when adjusted for age, and survival ofrenal
function is about eighty-five percent. Although not proven by scientific study, I believe
that the better outcome in patients with diffuse proliferative glomerulonephritis is attrib-
utable, in large part, to the use of immunosuppressive drugs such as azathioprine and
cyclophosphamide. Further, our experience and that of others suggest that treatment
should be continued for at least two years and should aim to transform the pattern ofrenal
injury to a more benign form. Renal biopsy is the only means to assess the effect oftreat-
ment. I also believe that there is a window ofopportunity to achieve a favorable outcome
because once significant irreversible damage occurs the action ofdrug treatment becomes
limited. One can only hope that more specific and less toxic therapy will become avail-
able in the near future.
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